BioSquare meeting identifies future trends, including patient-centered therapy and end to the blockbuster model
Pharmaceutical groups as well as biotechnology companies are calling for highly innovative technologies (nanotechnologies, medical devices, in-silico technologies, etc). This strategy of alliances between innovative technologies and the multi-disciplinary exchanges may be translated into the bioconvergence concept and the emergence of a more personalized medicine, ideas which were the core of BioSquare 2010, a meeting held earlier this month in Geneva, Switzerland, which attracted some 600 delegates.
As Bernadette Guagliata, chief executive of BioSquare, emphasized: 'BioSquare 2010 proved to be a condenser of expertise, bringing together during a highly-focused conference, the international decision makers of bioconvergence.
The conference identified a number of emerging trends:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze